A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

Summary

To learn if rivoceranib can help to control olfactory neuroblastoma. The safety of this drug in participants with olfactory neuroblastoma will also be studied.

Timeline

Start

2024-11-01

Primary completion

2024-11-05

Completion

2024-11-05

Outcome

Outcome not reported

Stopped (Enrollment): “PI Request--No Patient Accrual”

Drugs

Indications